Erlotinib inhibits progression to dysplasia in a colitis-associated colon cancer model

doi:10.3748/wjg.v17.i44.4858

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 17, Issue 44

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (3636)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-7) series, Tables (1-1) series.

Item

Count

PDF

326

HTML

2964

Figures (1-7)

199

Tables (1-1)

147

Sum=3636

Nov 28, 2011 (publication date) through Apr 23, 2024

Times Cited of This Article

Times Cited (9)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Original Article

World J Gastroenterol. Nov 28, 2011; 17(44): 4858-4866
Published online Nov 28, 2011. doi: 10.3748/wjg.v17.i44.4858

Full Size Figure Download Figure

Figure 1 Experimental design for development of colitis-associated dysplasia in a rat model and timeline for administration of erlotinib (10 mg/kg, ip). TNBS: Trinitrobenzene sulfonic acid.

Citation: Pagán B, Isidro AA, Cruz ML, Ren Y, Coppola D, Wu J, Appleyard CB. Erlotinib inhibits progression to dysplasia in a colitis-associated colon cancer model. World J Gastroenterol 2011; 17(44): 4858-4866
URL: https://www.wjgnet.com/1007-9327/full/v17/i44/4858.htm
DOI: https://dx.doi.org/10.3748/wjg.v17.i44.4858